查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球心臟消融设备市场
市场调查报告书
商品编码
1140702

2022-2029 年全球心臟消融设备市场

Global Cardiac Ablation Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

心臟消融设备市场规模预计将在 2021 年达到 40.672 亿美元，在 2029 年达到 108.943 亿美元，在预测期间（2022-2029 年）以 12.85% 的复合年增长率增长。我来了。

心臟消融术，一种用于改变/改变导致心律异常的心臟组织功能的非侵入性手术。心臟消融有多种类型，包括导管消融、手术消融和混合手术导管消融。心臟消融用于心律管理、开放手术和其他应用。

市场动态

主要驱动因素是心律失常患病率的上升、老年人口的增长、保健意识的提高以及对非侵入性手术的需求不断增加。

心律失常患病率的上升和研究活动的增加预计将推动市场增长。

预计心律失常的增加将推动市场。例如，根据 CDC2020 报告，每年有超过 750,000 人因房颤住院。该病每年还导致近 130,000 人死亡。因此，越来越多的心律失常病例正在推动市场。

预计在预测期内，不断增长的老年人口将提振市场。许多国家目前正面临与人口增长和老龄化相关的挑战。根据联合国经济和社会事务部 2019 年人口司的数据，未来 30 年，全球 60 岁及以上人口将增加两倍。根据世界卫生组织 (WHO) 的数据，65 岁及以上的人口预计将从 2010 年的 5.24 亿增长到 2050 年的 15 亿。一些慢性疾病的发病率，如心血管疾病和神经退行性疾□□病，往往与老年人口有关，并且变得越来越普遍。因此，老年人口的增加正在推动市场。

增加研究活动以确认消融设备的有效性和安全性也有望推动市场发展。例如，2019 年 8 月 19 日，约翰霍普金斯大学的科学家们将创建心臟上腔室的个性化数字复製品，并用它来指导对持续性心律失常患者的精准治疗，我成功了。 Loyola 还测试了一种新的导管消融系统，该系统可以深入心肌。

严格的政府法规和副作用预计会阻碍市场增长。

缺乏熟练的医护人员、严格的政府法规和副作用正在阻碍市场发展。其中，副作用的发生有望抑制市场。例如，中风、化学过敏、食道损伤和很少发生在普通人群中的完全心源性死亡。

行业分析

全球心臟消融设备市场根据各种行业因素（包括波特五力、监管分析、供应链分析、定价分析和未满足的需求）对市场进行了深入分析。

细分分析

在全球心臟消融设备市场中，射频消融设备部分预计将占据最大的市场份额

按产品类型，全球心臟消融设备市场可细分为射频 (RF) 消融设备、电消融设备、冷冻消融设备、超声消融设备和微波消融设备。

电消融设备进一步细分为氩等离子体/束凝固器和不可逆电穿孔系统。由于研究活动的增加，预计电灼设备将具有较高的增长率。例如，在心律学会第 39 届年度科学会议上展示其研究细节的研究人员 Heart Rhythm 已经开始了一项首次人体电穿孔消融研究，表明脉衝电场可以针对心房颤动中的特定组织进行报导。

冷冻消融设备进一步分为组织接触探针和组织喷雾探针。由于最近主要参与者的批准、收购和合併，预计冷冻消融设备将推动市场发展。例如，2021年1月，美敦力宣布其DiamondTemp消融系统获得美国FDA批准，用于治疗復发性阵发性房颤患者。

超声消融设备又分为高强度聚焦超声消融器、磁共振引导聚焦超声消融器和超声消融系统。预计最近的政府批准将在预测期内推动市场。例如，2019 年，Acutus Medical 的 AcQMap 接触地图软件获得了欧洲的批准。该系统中的新型导管使用超声和电组织传导映射来提供心臟内部的新型电生理实时视图。

全球心臟消融设备市场可按应用细分为心律管理、心臟直视手术等。

心律管理进一步分为心律失常、心房颤动和扑动以及心动过速。由于越来越多的研究和政府批准，预计心律管理部门将推动市场发展。 Loyola Medicine 是世界上仅有的两个提供新型导管消融系统的中心之一，该系统用于改善称为室性心动过速的危及生命的心律失常的预后。根据 2019 年 1 月 30 日发表在《核医学杂誌》一月刊上的一项新研究，碘-123-间碘芐基胍 (123I-MIBG) SPECT 成像与心臟磁共振成像 (MRI) 相结合。如果是这样，它可能会有所帮助识别容易发生心律失常的特定心臟组织亚群，使医生能够更好地抑制室性心动过速并缩短手术时间。通过这种方式，积极的研究活动正在推动市场。

区域分析

北美占全球心臟消融设备市场最大的市场份额

从地理位置上看，全球心臟消融设备市场分为五个主要区域。北美、欧洲、亚太地区、拉丁美洲、中东和非洲。

由于心律失常的患病率不断增加、基础设施完善、外科导管的大规模采用、政府支持的增加以及患者意识的提高，北美在全球心臟消融设备市场占据主导地位。预计市场规模将保持巨大在预测期内。

外科导管插入术的激增预计将提振市场。例如，根据美国心臟协会 (AHA) 的说法，导管消融术的成功率高达 90%，并发症风险低，并且可以让患者在几天内恢復正常活动。 Biosense-Webster、美敦力和波士顿科学等领先公司每年花费数百万美元研究和开发新设备，以提高成功率并减少手术并发症。我在这里。

心律失常病例的增加也推动了市场的发展。例如，2019 年，疾病控制和预防中心估计美国有 2.7 到 610 万人患有心房颤动。因此，越来越多的心律失常病例正在推动市场。

心臟消融设备製造商的出现也推动了市场的发展。例如，2022 年 2 月，美敦力公布了美国 FDA 批准的 Freezor 和 Freezor Xtra 心臟冷冻消融灶导管。这是 FDA 批准用于治疗儿科 AV 结折返性心动过速的首批消融导管。

竞争格局

心臟消融设备市场由众多参与者主导，例如波士顿科学公司、Epix Therapeutics、Acutus Medical、美敦力、AtriCure, Inc、Biosense Webster, Inc、St Jude Medical、雅培、西奈山健康系统公□□司。竞争激烈凶猛的。

主要参与者正在采取各种增长策略，例如产品发布、併购、合作伙伴关係和联盟，这有助于全球心臟消融设备市场的增长。例如：

  • 2022 年 8 月，美敦力宣布收购 Affere Inc.。此次收购将使 Metronic 能够扩大其心臟消融产品组合，以包括首个提供集成诊断和射频消融解决方案的心臟标测和导航平台。
  • 2021 年 10 月，波士顿科学宣布收购 Bayliss Medical。此次收购扩大了波士顿科学公司的电生理学和心臟产品组合。
  • 2021 年 6 月，波士顿科学公司宣布收购 Farapulse 的股份。 Farapulse 的脉衝场消融系统的加入扩大了波士顿的电生理学产品组合。用于治疗心房颤动的非热消融系统。
  • 2021年1月，美敦力宣布DiamondTemp消融系统获美国FDA批准用于治疗復发性阵发性房颤患者。它是第一个获得 FDA 批准的温度可控灌注射频消融系统。

值得关注的重点公司

波士顿科学公司

概览 Boston 是一家跨国生物医学工程公司。该公司生产用于介入心脏病学、神经血管介入、心臟外科、肿瘤外科、血管外科的医疗器械，并提供微创植入式心血管除颤器。成立于 1979 年，总部位于美国马萨诸塞州。

产品组合

MetriQ 泵。允许消融手术的开放式灌注系统。有助于最大限度地提高开放灌注程序的成功率。使用先进的消融技术改善患者治疗效果。

重大进展。 2021 年 1 月，波士顿科学公司宣布了一项收购移动心臟健康解决方案产品和服务的私人控股供应商预防解决方案公司的协议。

全球心臟消融设备市场报告包含大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 心律失常发病率增加
      • 老年人口增加
    • 限制因素
      • 出现副作用
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 监管分析
  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章按产品类型

  • 射频 (RF) 消融
    • 温控高频消融器
    • 液冷式高频消融器
    • 机器人导管操纵系统
  • 电烙术
    • 氩等离子/束流凝固器
    • 不可逆电穿孔系统
  • 冷冻消融
    • 组织接触探针
    • 组织喷雾探针
  • 超声消融
    • 高强度聚焦超声消融器
    • 磁共振引导聚焦超声消融器
    • 超声波消融系统
  • 微波消融装置
    • 微波热处理装置

第 7 章按应用程序

  • 心律管理
    • 心律失常
    • 心房颤动和扑动
    • 心动过速
  • 开腹手术
  • 其他

第 8 章最终用户

  • 医院
  • 门诊手术中心
  • 诊所
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 11 章公司简介

  • 波士顿科学公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Epix Therapeutics
  • Acutus Medical
  • Medtronic
  • AtriCure, Inc.
  • Biosense Webster, Inc.
  • St Jude Medical
  • Abbott
  • Mount Sinai Health System Inc

第12章 心臟消融设备的全球市场 - DataM

简介目录
Product Code: DMMD2046

Market Overview

Cardiac Ablation Devices Market size was valued US$ 4,067.2 million in 2021 and is estimated to reach US$ 10,894.3 million by 2029, growing at a CAGR of 12.85% during the forecast period (2022-2029).

Cardiac ablation, a non-invasive procedure to modify/alter the functions of the tissues in heart which causes abnormal heart rhythm. Catheter ablation, surgical ablation, and hybrid surgical catheter ablation are various types of cardiac ablation. Cardiac ablation is used in cardiac rhythm management, open surgery, and in other applications.

Market Dynamics

The major driving forces are the increasing number of people with cardiac arrhythmia, increasing geriatric population, rising healthcare awareness, and the growing demand for non-invasive procedures.

Increasing prevalence of cardiac arrhythmia and rising research activities are expected to drive market growth.

The rising number of cardiac arrhythmia is expected to drive the market. For instance, according to the CDC 2020 report, more than 750,000 hospitalizations occur each year because of atrial fibrillation. The condition also contributes to nearly 130,000 deaths each year. Thus, the increasing number of cardiac arrhythmia cases is driving the market.

Increasing geriatric population is expected to boost the market over the period of forecast. Many nations are now facing challenges related to the ongoing and increasing demographic shift in age among their populations. As per the Department of Economic and Social Affairs Population Division of United Nations 2019, the global population of 60 years old will double and those of 80 years old will triple in the next 30 years. As per the World Health Organization, the number of people of 65 or older is expected to grow from 524 million in 2010 to 1.5 billion in 2050. Development of several chronic diseases such as cardiovascular diseases and neurodegenerative diseases are often associated with and more common among the older age groups. Thus, the growing geriatric population is driving the market.

The increasing research activities to check the efficacy and safety of ablation devices are expected to boost the market. For instance, on August 19, 2019, Scientists at Johns Hopkins have successfully created personalized digital replicas of the upper chambers of the heart and used them to guide the precise treatment of patients suffering from persistent irregular heartbeats. Also, Loyola tested a new catheter ablation system that can reach deeper into the heart muscle.

Stringent government regulations and side effects are expected to hamper the market growth.

The lack of skilled medical professionals, stringent government regulations, and the onset of side effects are hampering the market. Among these, the onset of side effects is expected to restrain the market. For instance, stroke, chemical allergies, esophageal injury, or in rare cases, death of the complete heart is seen in less percentage of the total population.

Industry Analysis

The global cardiac ablation devices market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis and unmet needs.

Segment Analysis

Radiofrequency ablation devices segment is expected to hold the largest market share in global cardiac ablation devices market

The global cardiac ablation devices market can be segmented by product type into radiofrequency (RF) ablation devices, electrical ablation devices, cryoablation devices, ultrasound ablation devices, and microwave ablation devices.

Electric ablators are further segmented into argon plasma/beam coagulators and irreversible electroporation systems. The electrical ablation devices are expected to grow at a high rate, owing to the increased number of research activities. For instance, according to the researchers, who presented the study details at Heart Rhythm, the Heart Rhythm Society's 39th Annual Scientific Sessions, commenced a first-in-human electroporation ablation study and reported that pulsed electric fields could target the specific tissue for atrial fibrillation.

The cryoablation devices are further segmented into tissue contact probes and tissue spray probes. The cryoablation devices are expected to boost the market, owing to the recent approvals, acquisitions, and mergers by the key players. For instance, In Jan 2021, Medtronic announced that DiamondTemp ablation system got approved by U.S.FDA for treatment of patients that have recurrent, paroxysmal atrial fibrillation.

Ultrasound ablation devices are further segmented into high-intensity focused ultrasound ablators, magnetic resonance-guided focused ultrasound ablators and ultrasound ablation systems. It is expected to drive the market over the period of forecast, owing to the recent government approvals. For instance, in 2019, Acutus Medical won European approval for its AcQMap contact mapping software. The system's novel catheter uses ultrasound and electrical tissue conduction mapping to provide a novel electro physiologic live view inside the heart.

The global cardiac ablation devices market can be segmented by application into cardiac rhythm management, open-heart surgery, and others.

Cardiac Rhythm Management is further segmented into cardiac arrhythmia, atrial fibrillation and flutter, and tachycardia. The cardiac rhythm management segment is expected to boost the market, owing to the increased number of researches, government approvals, etc. Loyola Medicine is among the two centers in the world, offering a novel catheter ablation system used to improve treatment outcomes for a life-threatening heart rhythm disorder called ventricular tachycardia. On January 30, 2019, according to the new research published in the January issue of The Journal of Nuclear Medicine, the Iodine-123 metaiodobenzylguanidine (123I-MIBG) SPECT imaging, when combined with cardiac magnetic resonance imaging (MRI), helped to identify specific subsets of heart tissue more prone to arrhythmia, which may allow physicians to achieve improved ventricular tachycardia suppression and shorter procedure times. Thus, the growing number of research activities are driving the market.

Geographical Analysis

North America region holds the largest market share in the global cardiac ablation devices market

Geographically, the global cardiac ablation devices market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is dominating the global cardiac ablation devices market and is estimated to hold a significant market size over the forecast period owing to the increasing prevalence of cardiac arrhythmia's, presence of well-developed infrastructures, high volumes of catheterization for surgeries, increasing government support, and high patient awareness in the region.

The high volumes of catheterization for surgeries are expected to boost the market. For instance, according to the American Heart Association (AHA), catheter-based ablation procedures boast a 90 % success rate, having a lower risk of complications, and allow patients to resume the normal activities in a few days. Also, the leading companies such as Biosense Webster, Medtronic, and Boston Scientific spend millions of dollars each year researching and developing new devices to improve these success rates and to reduce complications during procedures.

The increasing number of cardiac arrhythmia cases is boosting the market. For instance, the Centre for Disease Control and Prevention in 2019, estimated that 2.7-6.1 million people in the US had atrial fibrillation. Thus, the rising number of cardiac arrhythmia cases are driving the market.

Also, the presence of key players manufacturing cardiac ablation devices are boosting the market. For instance, In Feb 2022, Medtronic announced U.S. FDA approved Freezor and Freezor Xtra cardiac cryoablation focal catheters. These are the first ablation catheters approved by FDA for the treatment of pediatric atrioventricular nodal reentrant tachycardia.

Competitive Landscape

The cardiac ablation devices market is highly competitive with presence of large number of players including Boston Scientific Corporation, Epix Therapeutics, Acutus Medical, Medtronic, AtriCure, Inc., Biosense Webster, Inc., St Jude Medical, Abbott and Mount Sinai Health System Inc.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the cardiac ablation devices market globally. For instance,

  • In Aug 2022, Medtronic announced its acquisition of Affere Inc. This acquisition will help metronic expand its portfolio of cardiac ablation by including 1st ever cardiac mapping and navigation platform that will provide integrated diagnostic and radiofrequency ablation solution.
  • In Oct 2021, Boston Scientific announced its acquisition of Baylis Medical Company. It will increase the electrophysiology and heart product portfolio of Boston Scientific.
  • In Jun 2021, Boston Scientific Corp. announced about exercising the acquisition of Farapulse Inc. remaining shares. It will expand Boston electrophysiology portfolio and include Pulse field ablation system of Farapulse. It is a non-thermal ablation system that is used for treating atrial fibrillation.
  • In Jan 2021, Medtronic announced that DiamondTemp ablation system got approved by U.S.FDA for treatment of patients that have recurrent, paroxysmal atrial fibrillation. It is the 1st FDA approved irrigated radiofrequency ablation system that is temperature controlled.

Key Companies to Watch

Boston Scientific Corporation:

Overview: Boston is a multinational biomedical engineering company. It manufactures medical devices that includes interventional cardiology, neurovascular intervention, cardiac surgery, oncology, vascular surgery etc. it also offers minimally invasive implantable cardiovascular defibrillator. It was founded in 1979 and is headquartered in Massachusetts, United States.

Product Portfolio:

MetriQ Pump: It is an open irrigated system that enables ablation procedures. It helps in maximizing the success of open irrigated procedure. With advanced ablation technology it improves patient outcomes.

Key Developments: In Jan 2021, Boston Scientific Corp. announced its agreement of acquisition of Preventice Solutions Inc., a private company that provides products of mobile cardiac health solutions and services.

The global cardiac ablation devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of cardiac arrhythmia
      • 4.1.1.2. The growing number of geriatric populations
    • 4.1.2. Restraints
      • 4.1.2.1. The onset of side effects
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. By Product type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 6.1.2. Market Attractiveness Index, By Product type Segment
  • 6.2. Radiofrequency (RF) Ablation
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.2.2.1. Temperature-controlled Radiofrequency Ablators
      • 6.2.2.2. Fluid-cooled Radiofrequency Ablators
      • 6.2.2.3. Robotic Catheter Manipulation Systems
  • 6.3. Electrical Ablation
    • 6.3.1. Introduction
    • 6.3.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.3.2.1. Argon Plasma/Beam Coagulators
      • 6.3.2.2. Irreversible Electroporation Systems
  • 6.4. Cryoablation
    • 6.4.1. Introduction
    • 6.4.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.4.2.1. Tissue Contact Probes
      • 6.4.2.2. Tissue Spray Probes
  • 6.5. Ultrasound Ablation
    • 6.5.1. Introduction
    • 6.5.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.5.2.1. High-intensity Focused Ultrasound Ablators
      • 6.5.2.2. Magnetic Resonance Guided Focused Ultrasound Ablators
      • 6.5.2.3. Ultrasound Ablation Systems
  • 6.6. Microwave Ablation
    • 6.6.1. Introduction
    • 6.6.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.6.2.1. Microwave Thermotherapy Devices

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Cardiac rhythm management
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 7.2.2.1. Cardiac Arrhythmia
      • 7.2.2.2. Atrial Fibrillation and Flutter
      • 7.2.2.3. Tachycardia
  • 7.3. Open surgery
  • 7.4. Others

8. By End-user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 8.1.2. Market Attractiveness Index, By End-user Segment
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
  • 8.3. Ambulatory surgical centers
  • 8.4. Clinics
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Boston Scientific Corporation
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Epix Therapeutics
  • 11.3. Acutus Medical
  • 11.4. Medtronic
  • 11.5. AtriCure, Inc.
  • 11.6. Biosense Webster, Inc.
  • 11.7. St Jude Medical
  • 11.8. Abbott
  • 11.9. Mount Sinai Health System Inc

LIST NOT EXHAUSTIVE

12. Global Cardiac Ablation Devices Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Method of Fixation
  • 12.3. Contact Us